Lilly tops analyst expectations despite shrinking profit, revenue

Back to TopCommentsE-mailPrintBookmark and Share

First-quarter profit fell 4 percent at Eli Lilly and Co., but the Indianapolis-based drugmaker easily beat the expectations of Wall Street analysts.

That prompted Lilly to boost its full-year profit forecast by 5 cents to 10 cents per share.

Lilly’s revenue and profit have been falling after it lost patent protection on two blockbuster drugs: the cancer drug Gemzar in late 2010 and the antipsychotic Zyprexa in late 2011.

But the company said sales in other parts of its business—including the antidepressant Cymbalta, the blood thinner Effient, animal health products and in China—all grew by 20 percent or more

Lilly’s quarterly revenue totaled $5.6 billion, down 4 percent from the previous year. Wall Street analysts were expecting revenue of $5.36 billion, according to a survey by Thomson Reuters.

"Notwithstanding the negative effect of the expiration of the Zyprexa patent in the U.S. and many international markets, Lilly demonstrated strong underlying growth in other products and key regions,” Lilly CEO John Lechleiter said in a prepared statement.

Lilly’s profit in the first quarter totaled $1.01 billion, or 91 cents per share, down from $1.06 billion, or 95 cents per share, in the same quarter a year ago.

Wall Street analysts were expecting 78 cents per share in the most recent quarter, according to a Thomson Reuters.

The decline in profit was actually much larger than it seems. A year ago, Lilly booked some one-time charges for research deals with other companies and for reductions in personnel. Excluding all such charges in both years, Lilly’s per-share profit would have fallen by nearly 26 percent, from $1.24 per share in the first quarter a year ago to 92 cents per share this year.

For all of 2012, Lilly now expects per-share profit in a range of $3.15 to $3.30, excluding a penny-per-share charge taken in the first quarter for a one-time restructuring move. In January, Lilly had predicted it would earn 2012 profit of $3.10 per share to $3.20 per share.

Lilly shares were up 52 cents, or 1.3 percent, in late-morning trading, to $40.48 each. They are down 3.1 percent since the beginning of the year.


  • Zyprexa issues
    Eli Lilly did make $65 billion on Zyprexa and they still expect to capture 20% of the US market as well as a billion year on ZyprexaXR.

    The patent only expires in the US and some Euro,Lilly announced they have an *authorized* distributor of generic Zyprexa.

    I am keenly interested in how they resolve remaining Zyprexa litigation.

    PTSD treatment for Veterans found ineffective.
    Zyprexa can cause diabetes.
    I took Zyprexa Olanzapine a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.
    *FIVE at FIVE*
    The Zyprexa antipsychotic drug,whose side effects can include weight gain and diabetes, was sold to Veterans,children in foster care, elderly in nursing homes.
    *Five at Five* was the Zyprexa sales rep slogan, meaning *5mg dispensed at 5pm would keep patients quiet*.

    *Tell the truth don't be afraid*-- Daniel Haszard
    FMI zyprexa-victims(dot)com

Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ